# Study to Evaluate Effects of Vorinostat and HXTC on Persistent HIV-1 Infection in HIV-Infected Subjects Started on Antiretroviral Therapy (ART)

> **NCT03212989** · PHASE1 · COMPLETED · sponsor: **University of North Carolina, Chapel Hill** · enrollment: 17 (actual)

## Conditions studied

- HIV-1 Infection

## Interventions

- **DRUG:** Vorinostat
- **BIOLOGICAL:** HXTC

## Key facts

- **NCT ID:** NCT03212989
- **Lead sponsor:** University of North Carolina, Chapel Hill
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-06-27
- **Primary completion:** 2022-06-07
- **Final completion:** 2022-07-05
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2023-05-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03212989

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03212989, "Study to Evaluate Effects of Vorinostat and HXTC on Persistent HIV-1 Infection in HIV-Infected Subjects Started on Antiretroviral Therapy (ART)". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03212989. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*